Fig. 3.

Med1^-/- MEF are resistant to cytotoxicity of antitumor agents. (A) Detection of apoptotic mono- and oligonucleosomes in MEF with different genotypes treated with increasing doses of MNNG for 48 h. Nucleosome enrichment is computed with respect to vehicle-treated cells. (B) TUNEL assay of Med1^+/+ (a and b) and Med1^-/- (c and d) MEF treated with 10 μg/ml MNNG for 6 h: a and c, DAPI staining; b and d, TUNEL staining. (C–E) Survival analysis (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay) at 3 and 5 days of MEF with different genotypes treated with 20 μM oxaliplatin, 20 μM irinotecan, and 10 μM 5-FU, respectively. (F) Survival analysis (TUNEL assay) of MEF with different Med1 genotype infected with amphotropic ASV at the indicated multiplicity of infection. The negative and positive controls are uninduced (ATR wild type) GM847 human fibroblasts and GM847 cells induced with doxycycline to express a dominant negative ATR mutant (d.n.), respectively.